The HLS Therapeutics team manages a growing portfolio of commercial stage branded medicines including CLOZARIL® (clozapine) and VASCEPA® (icosapent ethyl). We source our products directly from originators and from best-in-class manufacturing partners, ensuring they meet the highest standards of quality and compliance with stringent FDA and Health Canada regulations. By ensuring reliable market access to these essential therapies, we create value and build trust with healthcare providers, patients, and other stakeholders.

Company Highlights


2023 Revenue


2023 Adj. EBITDA


Cash Flow from Operations

Investor Highlights

Latest News

View All News